Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression
Background: This study aims to describe COVID-19–related clinical outcomes after immunotherapies (ICIs) for cancer patients. Methods: In this meta-analysis, we searched databases to collect data that addressed outcomes after immunotherapies (ICIs) during the COVID-19 pandemic. The primary endpoint w...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2571-841X/5/3/31 |
| _version_ | 1827657051520630784 |
|---|---|
| author | Mona Kamal Massimo Baudo Jacinth Joseph Yimin Geng Aiham Qdaisat |
| author_facet | Mona Kamal Massimo Baudo Jacinth Joseph Yimin Geng Aiham Qdaisat |
| author_sort | Mona Kamal |
| collection | DOAJ |
| description | Background: This study aims to describe COVID-19–related clinical outcomes after immunotherapies (ICIs) for cancer patients. Methods: In this meta-analysis, we searched databases to collect data that addressed outcomes after immunotherapies (ICIs) during the COVID-19 pandemic. The primary endpoint was COVID-19–related mortality. Secondary endpoints included COVID-related hospital readmission, emergency room (ER) visits, opportunistic infections, respiratory complications, need for ventilation, and thrombo-embolic events. Pooled event rates (PERs) were calculated and a meta-regression analysis was performed. Results: A total of 262 studies were identified. Twenty-two studies with a total of forty-four patients were eligible. The PER of COVID-19–related mortality was 39.73%, while PERs of COVID-19–related ER visits, COVID-19–related pulmonary complications, and COVID-19–related ventilator needs were 40.75%, 40.41%, and 34.92%, respectively. The PER of opportunistic infections was 34.92%. The PERs of the use of antivirals, antibiotics, steroids, prophylactic anticoagulants, and convalescent plasma were 62.12%, 57.12%, 51.36%, 41.90%, and 26.48%, respectively. There was a trend toward an association between previous respiratory diseases and COVID-19–related mortality. Conclusion: The rates of COVID-19–related mortality, ER visits, pulmonary complications, need for a ventilator, and opportunistic infections are still high after ICIs during the COVID-19 pandemic. There was a trend toward an association between previous respiratory diseases and COVID-19–related mortality. |
| first_indexed | 2024-03-09T22:36:50Z |
| format | Article |
| id | doaj.art-92bb7870b4424f7c81c65dbd211afac7 |
| institution | Directory Open Access Journal |
| issn | 2571-841X |
| language | English |
| last_indexed | 2024-03-09T22:36:50Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Reports |
| spelling | doaj.art-92bb7870b4424f7c81c65dbd211afac72023-11-23T18:46:55ZengMDPI AGReports2571-841X2022-07-01533110.3390/reports5030031Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-RegressionMona Kamal0Massimo Baudo1Jacinth Joseph2Yimin Geng3Aiham Qdaisat4Department of Symptom Research, Unit 1450, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USADepartment of Cardiac Surgery, Spedali Civili di Brescia, 25123 Brescia, ItalyDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAResearch Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USABackground: This study aims to describe COVID-19–related clinical outcomes after immunotherapies (ICIs) for cancer patients. Methods: In this meta-analysis, we searched databases to collect data that addressed outcomes after immunotherapies (ICIs) during the COVID-19 pandemic. The primary endpoint was COVID-19–related mortality. Secondary endpoints included COVID-related hospital readmission, emergency room (ER) visits, opportunistic infections, respiratory complications, need for ventilation, and thrombo-embolic events. Pooled event rates (PERs) were calculated and a meta-regression analysis was performed. Results: A total of 262 studies were identified. Twenty-two studies with a total of forty-four patients were eligible. The PER of COVID-19–related mortality was 39.73%, while PERs of COVID-19–related ER visits, COVID-19–related pulmonary complications, and COVID-19–related ventilator needs were 40.75%, 40.41%, and 34.92%, respectively. The PER of opportunistic infections was 34.92%. The PERs of the use of antivirals, antibiotics, steroids, prophylactic anticoagulants, and convalescent plasma were 62.12%, 57.12%, 51.36%, 41.90%, and 26.48%, respectively. There was a trend toward an association between previous respiratory diseases and COVID-19–related mortality. Conclusion: The rates of COVID-19–related mortality, ER visits, pulmonary complications, need for a ventilator, and opportunistic infections are still high after ICIs during the COVID-19 pandemic. There was a trend toward an association between previous respiratory diseases and COVID-19–related mortality.https://www.mdpi.com/2571-841X/5/3/31ICIsCOVID-19cancermortalitymeta-analysis |
| spellingShingle | Mona Kamal Massimo Baudo Jacinth Joseph Yimin Geng Aiham Qdaisat Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression Reports ICIs COVID-19 cancer mortality meta-analysis |
| title | Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression |
| title_full | Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression |
| title_fullStr | Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression |
| title_full_unstemmed | Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression |
| title_short | Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression |
| title_sort | clinical outcomes after immunotherapies in cancer setting during covid 19 era a systematic review and meta regression |
| topic | ICIs COVID-19 cancer mortality meta-analysis |
| url | https://www.mdpi.com/2571-841X/5/3/31 |
| work_keys_str_mv | AT monakamal clinicaloutcomesafterimmunotherapiesincancersettingduringcovid19eraasystematicreviewandmetaregression AT massimobaudo clinicaloutcomesafterimmunotherapiesincancersettingduringcovid19eraasystematicreviewandmetaregression AT jacinthjoseph clinicaloutcomesafterimmunotherapiesincancersettingduringcovid19eraasystematicreviewandmetaregression AT yimingeng clinicaloutcomesafterimmunotherapiesincancersettingduringcovid19eraasystematicreviewandmetaregression AT aihamqdaisat clinicaloutcomesafterimmunotherapiesincancersettingduringcovid19eraasystematicreviewandmetaregression |